Medicamen Biotech Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 5.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Medicamen Biotech reported audited results for FY26 with consolidated revenue of Rs. 20,088.29 Lacs, up 22% from Rs. 16,879.10 Lacs in FY25. Standalone revenue grew to Rs. 18,195.01 Lacs from Rs. 15,768.85 Lacs. Consolidated profit after tax improved significantly to Rs. 979.64 Lacs (up 49%) versus standalone PAT of Rs. 940.87 Lacs (essentially flat from Rs. 944.75 Lacs). The Board recommended a final dividend of Rs. 1 per equity share of Rs. 10 face value. Statutory auditors Rai Qimat & Associates issued unmodified (clean) opinions on both standalone and consolidated financials. The company appointed M/s SPB & Co as Cost Auditor and M/s Cheena & Associates as Internal Auditor for FY27. Cash position improved with cash equivalents at Rs. 3,108.40 Lacs (standalone) versus Rs. 358.03 Lacs in prior year.
Revenue growth of 22% on consolidated basis and 49% PAT growth are positive signals, though standalone PAT remained flat. The company has healthy cash reserves but operating cash flow was negative at Rs. 2,925.55 Lacs on standalone basis, which warrants monitoring. Clean audit opinion and dividend payment are shareholder-friendly.